IRBM_logos-no-strapline.png
IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders
12 juil. 2023 03h00 HE | IRBM
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s ROME, July 12, 2023 (GLOBE NEWSWIRE) -- IRBM,...
IRBM_logos-no-strapline.png
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
22 juin 2023 16h30 HE | IRBM
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...
IRBM_logos-no-strapline.png
IRBM Selected for Participation in National Chemical Biology Consortium
04 avr. 2023 03h00 HE | IRBM
ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...
ibn-iw-globe-2.png
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Josh Bartch, CEO of Mydecine Innovations Group Inc.
11 janv. 2022 08h17 HE | InvestorBrandNetwork (IBN)
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
87520785_101152591495741_6497961433500745728_o.jpg
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
25 août 2021 08h00 HE | Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
Inotiv_Logo_CMYK.png
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
15 juil. 2021 08h33 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Inotiv_Logo_CMYK.png
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® portfolio
12 juil. 2021 08h33 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Qualigen Therapeutics, Inc. - LOGO.jpg
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
08 mars 2021 08h30 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
LOGO.jpg
Interpace Biosciences Announces CFO Leadership Transition
04 févr. 2021 16h42 HE | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
logo.jpg
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
14 déc. 2020 08h07 HE | Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...